Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas

[1]  P. Woodman,et al.  TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly and Are Recruited to VPS4-induced Endosomes* , 2001, The Journal of Biological Chemistry.

[2]  T. Mak,et al.  A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Mak,et al.  p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Baylin,et al.  DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci , 2000, Nature Genetics.

[5]  N. Eberhardt,et al.  FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance , 2000, Clinical endocrinology.

[6]  S. Cohen,et al.  TSG101 protein steady-state level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence. , 2000, Cancer research.

[7]  S. Emr,et al.  Mammalian Tumor Susceptibility Gene 101 (TSG101) and the Yeast Homologue, Vps23p, Both Function in Late Endosomal Trafficking , 2000, Traffic.

[8]  A. Roquancourt,et al.  Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers , 1999, Oncogene.

[9]  M. Garabedian,et al.  Differential regulation of glucocorticoid receptor transcriptional activation via AF‐1‐associated proteins , 1999, The EMBO journal.

[10]  Stanley N Cohen,et al.  Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300 , 1999, Cancer.

[11]  Y-J Chen,et al.  Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers , 1999, British Journal of Cancer.

[12]  Shyr‐Yi Lin,et al.  Multiple truncated transcripts of TSG101 in gastrointestinal cancers , 1998, Journal of gastroenterology and hepatology.

[13]  A. Berchuck,et al.  Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. , 1998, Journal of the Society for Gynecologic Investigation.

[14]  Jan-Gowth Chang,et al.  Aberrant TSG101 transcripts in acute myeloid leukaemia , 1998, British journal of haematology.

[15]  Y. Chen,et al.  Perturbation of TSG101 protein affects cell cycle progression. , 1998, Cancer research.

[16]  Jiin‐Tsuey Cheng,et al.  Production and Characterization of Monoclonal Antibodies Against Tall Oncoprotein , 1998 .

[17]  S. Kato,et al.  A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. , 1998, Biochemical and biophysical research communications.

[18]  S. Cohen,et al.  Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Eugene V. Koonin,et al.  TSG101 may be the prototype of a class of dominant negative ubiquitin regulators , 1997, Nature Genetics.

[20]  A. Feinberg,et al.  Aberrant splicing but not mutations of TSG101 in human breast cancer. , 1997, Cancer research.

[21]  Stanley N Cohen,et al.  RETRACTED: The TSG101 Tumor Susceptibility Gene Is Located in Chromosome 11 Band p15 and Is Mutated in Human Breast Cancer , 1997, Cell.

[22]  Stanley N Cohen,et al.  tsg101: A Novel Tumor Susceptibility Gene Isolated by Controlled Homozygous Functional Knockout of Allelic Loci in Mammalian Cells , 1996, Cell.

[23]  M. Rugge,et al.  Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. , 1996, Cancer research.

[24]  J. Figge,et al.  Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas. , 1995, Experimental and molecular pathology.

[25]  M. Knowles,et al.  Deletion mapping of chromosome II in carcinoma of the bladder , 1995 .

[26]  J. Camonis,et al.  Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H. Safaii,et al.  Molecular genetic changes associated with ovarian cancer. , 1994, Gynecologic oncology.

[28]  L. Simms,et al.  Three non‐overlapping regions of chromosome arm 11p allele loss identified in infantile tumors of adrenal and liver , 1993, Genes, chromosomes & cancer.

[29]  R. Lothe,et al.  Frequent loss of 11p13 and 11p15 loci in male germ cell tumours , 1993, Genes, chromosomes & cancer.

[30]  R. Stahel,et al.  Allelic loss on the short arm of chromosome 11 in non‐small‐cell lung cancer , 1991, International journal of cancer.

[31]  A. Reeve,et al.  Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells , 1989, Molecular and cellular biology.

[32]  Iqbal Unnisa Ali,et al.  Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia , 1987 .